placeholder

Download This Report

Eliminating Protein Aggregates
Linked to Immune Response
A Revolutionary Syringe
Technology for Biologic
Therapeutics

By Christopher Weikart, PhD, Chief Scientist, SIO2 Materials Science

Therapeutic biologic drugs serve an omnipresent role in treating a wide range of diseases today. A growing body of literature, however, indicates that injectable biologic proteins can produce adverse drug reactions in both animals and humans....  

placeholder

placeholder

SiO2 Materials Science is a privately-owned U.S. advanced materials science corporation, involved in introducing breakthrough disruptive technology. While SiO2 was established in 2010, much of the core team has been working together since the 1950’s. The company is currently located in Auburn, Alabama close to Atlanta, Georgia and is in the process of developing a new facility located near Basel, Switzerland to manufacture the same six-sigma plus quality in all of its facilities. The company has deep partnerships with leading professors in the leading research universities such as University of California, University of Chicago, MIT, and CalTech.